Dr. Nancy Reid, MHA, DHSc, PA-C, DFAAPA
Objective: This review seeks to determine if current evidence supports the use of sodium-glucose cotransporter-2 inhibitors (SGLT2I) to improve renal outcomes in the adult population with type two diabetes mellitus (T2DM). Methods: PubMed and Google Scholar were interrogated for high-quality studies that included only systematic reviews and meta-analyses completed since 2017. Six research articles were analyzed and included in this review. Results: Compared to placebo, SGLT2Is reduce the risk of progression to end-stage renal disease, risk of acute kidney injury, and reduce the death rate from renal disease in patients with T2DM. Conclusion: Sodium-glucose cotransporter-2 inhibitors not only improve glycemic control but have also been shown to improve renal disease outcomes. It is imperative to use SGLT2I therapy early in diabetic pharmacologic management to reduce the enormous financial and medical burden of chronic kidney disease in patients with T2DM. Keywords: SGLT2, type two diabetes, renal outcomes, diabetic nephropathy, renal disease.
Nordby S. Effect of SGLT2Is on Renal Outcomes in Diabetes. Lynchburg Journal of Medical Science. 2021; 3(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.